| 摘要 |
Disclosed are methods for the detection, diagnosis and prediction of tamoxifen-resistant breast cancer. Genetic and antibody probes and methods useful in determining the presence and monitoring the progression of breast cancer are also described. The methods involve determining polypeptide or mRNA expression of the genes encoding the angiogenic agents or receptors TIE-2, EDNRA, TGFbeta3, TGFRbetaIII, VEGFR1, VEGF or bFGFR. Also described are procedures for combination therapies utilizing antiangiogenic agents or gene therapy directed towards TIE-2, EDNRA, TGFbeta3, TGFRbetaIII, VEGFR1, VEGF or bFGFR, in combination with tamoxifen treatment of breast cancer.
|
